<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

    <MetaVariables>
        <Submitter/>
        <Method/>
    </MetaVariables>
    <MetaLinks/>

    <Projects>
        <Project/>
    </Projects>

    <Studies>

        <Study source="dbGaP" accession="phs000920.v4.p2" parentStudy="phs000920.v4.p2" createDate="2019-12-04"
               modDate="2020-02-11">

            <Configuration>
                <Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Esteban Burchard, MD, MPH</td><td>University of California, San Francisco, CA, USA</td></tr>
		<tr><td>Funding Sources</td><td>1R01HL117004-03</td><td>National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
                <StudyNameEntrez>NHLBI TOPMed - NHGRI CCDG: Genes-Environments and Admixture in Latino Asthmatics (GALA
                    II)
                </StudyNameEntrez>
                <StudyNameReportPage>NHLBI TOPMed - NHGRI CCDG: Genes-Environments and Admixture in Latino Asthmatics
                    (GALA II)
                </StudyNameReportPage>
                <StudyTypes>
                    <StudyType>Case Set</StudyType>
                </StudyTypes>
                <Description><![CDATA[
<p>This is a case-only pharmacogenetic study of bronchodilator drug response among racially admixed Latino children with asthma. Each participant had two spirometry measurements using the KoKo PFT System. With the first spirometry test, participant was administered with 4 puffs of HFA Albuterol. The second albuterol measurement was based on age, for participants under 16 years of age, additional 2 puffs were administered and for those over 16 years of age, additional 4 puffs were administered. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants are 8-21 years old at time of recruitment. Children with asthma have physician-diagnosed asthma, symptoms and medications.</p> <p>Comprehensive phenotypic data for GALAII study participants are available through dbGaP <a href="./study.cgi?study_id=phs001180">phs001180</a>.</p>]]>
                </Description>
                <StudyInEx><![CDATA[
<p><b>Eligibility</b></p> <p>Subjects meeting the following criteria will be eligible for participation: <ol> <li>Ages between 8 and 21 years old</li> <li>Parents and Grandparents of the same ethnicity [self-identified]</li> <li>History of asthma [physician diagnosed or currently taking asthma medication]</li> <li>Having experienced symptoms of coughing, wheezing or shortness of breath in the past 2 years</li> <li>No respiratory infections for &#8805; 6 weeks</li> <li>No asthma exacerbations for &#8805; 6 weeks</li> <li>&#8804; 10 pack year smoking history, no smoking in the last year</li> <li>If pregnant, &lt; 3rd trimester</li> <li>No other history of lung diseases</li> </ol> </p>]]>
                </StudyInEx>
                <StudyProjects>
                    <Project/>
                </StudyProjects>
                <Publications>
                    <Publication>
                        <Pubmed pmid="19930545"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="20067482"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="20647190"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="20673084"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="21304981"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="21804549"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="21621256"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="22552109"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="22607992"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="22502797"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="23040885"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="23128226"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="23146381"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="23392439"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="23684070"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="23992748"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="23750510"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="23457522"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="24050698"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="24385924"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="24406073"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="24495433"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="24654704"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="24697756"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="24824216"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="24926019"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="25085501"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="25116239"/>
                    </Publication>
                    <Publication>
                        <Pubmed pmid="25301036"/>
                    </Publication>
                </Publications>
                <Diseases>
                    <Disease vocab_source="MESH" vocab_term="Lung Diseases"/>
                </Diseases>
                <Attributions>
                    <Header title="Principal Investigator">
                        <AttName>Esteban Burchard, MD, MPH</AttName>
                        <Institution>University of California, San Francisco, CA, USA</Institution>
                    </Header>
                    <Header title="Funding Sources">
                        <AttName>1R01HL117004-03</AttName>
                        <Institution>National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda,
                            MD, USA
                        </Institution>
                    </Header>
                </Attributions>
                <DisplayPublicSummary>yes</DisplayPublicSummary>
                <StudyURLs>
                    <Url name="Study Populations and Research Staff"
                         url="https://pharm.ucsf.edu/burchard/research/study-populations"/>
                </StudyURLs>
                <StudyHistory><![CDATA[
<p><b>Time Line</b> <ul> <li>February 2006 - First qualifying participant</li> <li>Spring 2013 - Genome Wide Association Study completed</li> <li>December 2014 - Whole Genome Sequencing</li> </ul> </p>]]>
                </StudyHistory>
                <ConsentGroups>
                    <ConsentGroup groupNum="2" shortName="DS-LD-IRB-COL"
                                  longName="Disease-Specific (Lung Diseases, IRB, COL)"/>
                </ConsentGroups>
            </Configuration>

            <AuthorizedAccess>
                <DacInfo ssDacId="0">
                    <DacName>NHLBI</DacName>
                    <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
                    <DacEmail>0</DacEmail>
                    <DacPhone/>
                    <DacUrl/>
                </DacInfo>
                <Policy Policy_ID="phs000920.v4.p2_policy" ref_ssDacId="0">
                    <DisplayResearchStatement>yes</DisplayResearchStatement>
                    <DisplayPublicSummary>yes</DisplayPublicSummary>
                    <EmbargoLength>0</EmbargoLength>
                    <YearsUntilRenewal>1</YearsUntilRenewal>
                    <WeeksCancelRequest>8</WeeksCancelRequest>
                    <PdfSupplementReqired>yes</PdfSupplementReqired>
                    <AcknowledgementText>
                        <para>
                            http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000920.v4.p2
                        </para>
                    </AcknowledgementText>
                    <DocumentSet>
                        <DataUseCertificate Label="Data Use Certificate"
                                            FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000920.v4.p2"
                                            FileName=""/>
                    </DocumentSet>
                </Policy>
                <ConsentGroups>
                    <ParticipantSet groupNum-REF="2">
                        <ConsentName>Disease-Specific (Lung Diseases, IRB, COL)</ConsentName>
                        <ConsentAbbrev>DS-LD-IRB-COL</ConsentAbbrev>
                        <UseLimitation>Use of the data must be related to Lung Diseases.
                            Requestor must provide documentation of local IRB approval.
                            Requestor must provide a letter of collaboration with the primary study investigator(s).
                            There is one consent group for this study: DS-LD-IRB-COL.
                            Use of the data must be related to Lung Diseases.
                            Requestor must provide documentation of local IRB approval(please note that only full or
                            expedited approvals will be accepted).
                            Requestor must provide a letter of collaboration with the primary study investigator(s).
                        </UseLimitation>
                        <IrbRequired>Yes</IrbRequired>
                    </ParticipantSet>
                </ConsentGroups>
            </AuthorizedAccess>
            <Documents>
                <Document phd="phd007493.2" type="protocol" createDate="2018-07-06" modDate="2020-02-10">
                    <OrigName>WGS Methods Freeze5b_180705.docx</OrigName>
                    <DisplayName>TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2</DisplayName>
                    <Description>TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2</Description>
                    <displayStatus>stage-2</displayStatus>
                    <xmlStatus>develop</xmlStatus>
                </Document>
                <Document phd="phd008024.1" type="protocol" createDate="2019-09-25" modDate="2020-02-11">
                    <OrigName>TOPMed_WGS_Methods_Freeze8.docx</OrigName>
                    <DisplayName>TOPMed Whole Genome Sequencing Methods: Freeze 8</DisplayName>
                    <Description>TOPMed Whole Genome Sequencing Methods: Freeze 8</Description>
                    <displayStatus>stage-2</displayStatus>
                    <xmlStatus>develop</xmlStatus>
                </Document>
            </Documents>


        </Study>

    </Studies>

</GaPExchange>
